Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
8.34M
-
Number of holders
-
10
-
Total 13F shares, excl. options
-
300K
-
Shares change
-
+222K
-
Total reported value, excl. options
-
$217K
-
Value change
-
+$152K
-
Number of buys
-
7
-
Number of sells
-
-2
-
Price
-
$0.72
Significant Holders of Pasithea Therapeutics Corp. - Common Stock, $0.0001 par value per share (KTTA) as of Q2 2025
11 filings reported holding KTTA - Pasithea Therapeutics Corp. - Common Stock, $0.0001 par value per share as of Q2 2025.
Pasithea Therapeutics Corp. - Common Stock, $0.0001 par value per share (KTTA) has 10 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 300K shares
of 8.34M outstanding shares and own 3.6% of the company stock.
Largest 10 shareholders include AdvisorShares Investments LLC (194K shares), CITADEL ADVISORS LLC (46.9K shares), UBS Group AG (42.1K shares), LPL Financial LLC (10K shares), Hurley Capital, LLC (3.69K shares), RAYMOND JAMES FINANCIAL INC (1.58K shares), Tower Research Capital LLC (TRC) (1.26K shares), SBI Securities Co., Ltd. (1.05K shares), JPMORGAN CHASE & CO (150 shares), and BANK OF AMERICA CORP /DE/ (62 shares).
This table shows the top 10 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.